Physician profile
Joseph E Murray
NPI 1235226101
$7,273.89
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $1,608 · 2021: $1,891 · 2022: $1,919 · 2023: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,174.67 | 2019-2023 | Ozempic, Rybelsus |
| Abbott Laboratories | $701.95 | 2020-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $684.26 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $608.00 | 2019-2023 | Mounjaro, Lyumjev, Humulin |
| Merck Sharp & Dohme LLC | $542.96 | 2019-2023 | Steglujan, Steglatro, Januvia |
| Sanofi-Aventis U.S. LLC | $321.25 | 2020-2023 | |
| Dexcom, INC. | $286.25 | 2020-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $273.43 | 2019-2023 | Evenity, Prolia |
| Abbvie INC. | $264.06 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $264.04 | 2019-2020 | |
| Antares Pharma, INC. | $259.82 | 2019-2022 | |
| Corcept Therapeutics | $230.15 | 2020-2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $211.95 | 2021-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.64 | 2020-2023 | Jardiance |
| Medtronic Minimed, INC. | $185.00 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $152.32 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $118.84 | 2019-2023 | Unithroid |
| Ibsa Pharma INC. | $113.28 | 2021-2023 | Tirosint, Licart |
| Medtronic, INC. | $104.56 | 2021-2023 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $92.27 | 2022-2023 | |
| Becton, Dickinson and Company | $85.55 | 2020-2022 | |
| Clarus Therapeutics INC. | $48.43 | 2021 | |
| Radius Health, INC. | $43.96 | 2022-2023 | |
| Lifescan, INC. | $41.94 | 2020 | |
| Alexion Pharmaceuticals, INC. | $36.55 | 2021-2022 | |
| Embecta Corp. | $35.08 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ultragenyx Pharmaceutical INC. | $30.76 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $26.04 | 2022 | |
| Acerus Pharmaceuticals Corporation | $25.94 | 2022 | |
| Pfizer INC. | $17.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.81 | 2021 | |
| Rochester Medical Corporation | $14.83 | 2021 | |
| Grt US Holding, INC. | $14.79 | 2021 | |
| Mannkind Corporation | $14.34 | 2021 | |
| Insulet Corporation | $13.01 | 2020 | |
| Alfasigma USA, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.